Investors

Investor Overview

Synta Overview

Our mission at Synta is to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. We aim to create the best place for the best people to create breakthrough drugs that change medical... More >>

Recent NewsMore >>
DateTitle 
12/12/14Synta Announces Presentation of Results from an Investigator-Sponsored Phase 1 Trial of Ganetespib in HER2+ Metastatic Breast Cancer at the 2014 San Antonio Breast Cancer Symposium
SAN ANTONIO--(BUSINESS WIRE)--Dec. 12, 2014-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced presentation of preliminary results from an investigator-sponsored phase 1 trial, designed to evaluate ganetespib in combination with paclitaxel and trastuzumab in women with HER2+ metastatic breast cancer (MBC) refractory to other HER2 inhibitors. The results are being presented during a poster session at the 2014 San Antonio Breast Cancer Symposium ... 
Printer Friendly Version
12/10/14Synta Reports Inducement Grants to New Chief Operating Officer and New Chief Financial Officer
LEXINGTON, Mass.--(BUSINESS WIRE)--Dec. 10, 2014-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the grant of inducement awards to its newly appointed Executive Vice President and Chief Operating Officer, Chen Schor, and its newly appointed Senior Vice President and Chief Financial Officer, Marc Schneebaum. The awards were approved by the Board's Compensation Committee and ratified by the full Board on December 1, 2014 as an inducement mater... 
Printer Friendly Version
12/04/14Synta Strengthens Management Team with Two Executive Appointments
-Chen Schor Named Chief Operating Officer; Marc Schneebaum Named Chief Financial Officer- LEXINGTON, Mass.--(BUSINESS WIRE)--Dec. 4, 2014-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the appointment of Chen Schor as the Company’s Executive Vice President and Chief Operating Officer and Marc Schneebaum as the Company’s Senior Vice President and Chief Financial Officer, both effective as of December 8, 2014. Mr. Schneebaum will ... 
Printer Friendly Version
11/19/14Synta Announces Presentation on Hsp90 inhibitor Drug Conjugate Platform at 26th EORTC-NCI-AACR Symposium
LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 19, 2014-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that a poster highlighting preclinical results from its Hsp90 inhibitor Drug Conjugate (HDC) platform is being presented at the 26th EORTC-NCI-AACR Symposium in Barcelona. “This poster highlights our ongoing evaluation of multiple candidates from the HDC platform. The preclinical results for our lead candidates not only demonstrate... 
Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Stock Quote
SNTA (Common)
ExchangeNASDAQ (US Dollar)
Price$2.80
Change (%) Stock is Down 0.06 (2.10%)
Volume1,333,843
Data as of 12/19/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Synta 2013 Form 10-K